Given the limited data on the efficacy of ALK inhibitors in pretreated patients with ALK fusion-positive gastrointestinal (GI) cancers, an international data set and molecular case series of GI tumors were analyzed. The gene discussed is ALK; the disease is digestive system neoplasm.